Trials / Completed
CompletedNCT04148937
A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer
A Phase 1 Multicenter Global First in Human Study of the CD73 Inhibitor LY3475070 as Monotherapy or in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 52 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The reason for this study is to see if the CD73 inhibitor LY3475070 alone or in combination with pembrolizumab is safe and effective in participants with advanced cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3475070 | Administered orally |
| DRUG | Pembrolizumab | Administered IV |
Timeline
- Start date
- 2020-01-16
- Primary completion
- 2021-05-12
- Completion
- 2022-06-20
- First posted
- 2019-11-04
- Last updated
- 2024-04-05
- Results posted
- 2024-04-05
Locations
12 sites across 3 countries: United States, Australia, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04148937. Inclusion in this directory is not an endorsement.